RxDoctor Payments Data

Jo Kim, DO

Internal Medicine · Duluth, GANPI 1205092921

Payments from drug & device makers

$3,820in general payments, 2019–2025

Across 111 payments — averaging $34.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$567
  • Novo Nordisk$486
  • AbbVie$342
  • Pfizer$201
  • Amarin Pharma, Inc.$163
  • plus $595 from 15 others

What the payments were for

  • Food & beverage$3,814100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,820 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$28,605
Medicare patients
49
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase67$124,211
Diclofenac Epolamine107$101,086
FarxigaDapagliflozin Propanediol64$91,435
OzempicSemaglutide53$63,261
JanuviaSitagliptin Phosphate49$51,918
ProliaDenosumab30$51,358
VascepaIcosapent Ethyl45$38,169
JardianceEmpagliflozin35$37,099
JanumetSitagliptin Phos/Metformin Hcl21$34,695
Lidocaine82$23,842
ZtlidoLidocaine17$20,312
ZenpepLipase/Protease/Amylase14$19,737
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$18,480
EliquisApixaban23$18,000
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$342$124,21167 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,466$109,91587 claims
MerckJanuvia, Janumet$153$86,61370 claims
Novo NordiskOzempic$486$63,26153 claims
AmgenProlia$567$51,35830 claims
GSKTrelegy Ellipta, Shingrix, Arexvy, Breo Ellipta$42$41,948107 claims
PfizerEliquis, Abrysvo$201$24,27843 claims
Scilex Pharmaceuticals Inc.Ztlido$35$20,31217 claims
Aimmune Therapeutics, Inc.Zenpep$15$19,73714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Duluth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →